Lung Cancer

Afatinib, Osimertinib Sequence Shows Promise for EGFR-Positive NSLC
August 10, 2020
ByHannah Slater

The GioTag study demonstrated that sequential afatinib and osimertinib improved overall survival among patients from the US with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a T790M resistance mutation.

FDA Approves Guardant360 CDx for Comprehensive Genomic Profiling in All Solid Cancers
August 10, 2020
ByHannah Slater

The FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with any solid malignant neoplasm.

Lorlatinib Improves PFS Compared to Crizotinib for Patients with ALK-Positive NSCLC
August 06, 2020
ByMatthew Fowler

Pfizer Inc.’s phase 3 CROWN trial examining lorlatinib to treat patients with ALK-positive NSCLC met its primary end point of improving progression-free survival when compared to crizotinib.